Irene Piaceri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/855089/publications.pdf

Version: 2024-02-01

55 papers	1,937 citations	430874 18 h-index	265206 42 g-index
55 all docs	55 docs citations	55 times ranked	4159 citing authors

#	Article	IF	Citations
1	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
2	A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
3	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
4	Genetics of familial and sporadic Alzheimer s disease. Frontiers in Bioscience - Elite, 2013, E5, 167-177.	1.8	166
5	Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiology of Aging, 2014, 35, 934.e7-934.e10.	3.1	134
6	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. Biological Psychiatry, 2013, 74, 384-391.	1.3	105
7	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
8	Folate, Homocysteine, Vitamin B12, and Polymorphisms of Genes Participating in One-Carbon Metabolism in Late-Onset Alzheimer's Disease Patients and Healthy Controls. Antioxidants and Redox Signaling, 2012, 17, 195-204.	5.4	60
9	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2904.e13-2904.e26.	3.1	48
10	A PALB2 germline mutation associated with hereditary breast cancer in Italy. Familial Cancer, 2010, 9, 181-185.	1.9	39
11	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
12	Alzheimerâ€™s Disease Progression: Factors Influencing Cognitive Decline. Journal of Alzheimer's Disease, 2017, 61, 785-791.	2.6	37
13	Mitochondria and Alzheimer's disease. Journal of the Neurological Sciences, 2012, 322, 31-34.	0.6	35
14	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	3.1	35
15	Tomm40 polymorphisms in Italian Alzheimerâ€™s disease and frontotemporal dementia patients. Neurological Sciences, 2013, 34, 995-998.	1.9	28
16	Epigenetic Modifications in Alzheimer's Disease: Cause or Effect?. Journal of Alzheimer's Disease, 2014, 43, 1169-1173.	2.6	27
17	The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimerâ€™s disease: a 9-year follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 471-482.	3.2	25
18	Lack of Implication for CALHM1 P86L Common Variation in Italian Patients with Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 37-41.	2.6	18

#	Article	IF	Citations
19	Imaging and Cognitive Reserve Studies Predict Dementia in Presymptomatic Alzheimer's Disease Subjects. Neurodegenerative Diseases, 2014, 13, 157-159.	1.4	18
20	Genetic Counseling and Testing for Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Journal of Alzheimer's Disease, 2016, 51, 277-291.	2.6	18
21	Ataxia-telangiectasia mutated (ATM) genetic variant in Italian centenarians. Neurological Sciences, 2013, 34, 573-575.	1.9	17
22	Tumor Necrosis Factor Î± Influences Phenotypic Plasticity and Promotes Epigenetic Changes in Human Basal Forebrain Cholinergic Neuroblasts. International Journal of Molecular Sciences, 2020, 21, 6128.	4.1	17
23	Genetics of Alzheimerâ€™s Disease and Frontotemporal Dementia. Current Molecular Medicine, 2014, 14, 993-1000.	1.3	16
24	Implication of a Genetic Variant at PICALM in Alzheimer's Disease Patients and Centenarians. Journal of Alzheimer's Disease, 2011, 24, 409-413.	2.6	15
25	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
26	Influence of ApoE Genotype and Clock T3111C Interaction with Cardiovascular Risk Factors on the Progression to Alzheimerâ€™s Disease in Subjective Cognitive Decline and Mild Cognitive Impairment Patients. Journal of Personalized Medicine, 2020, 10, 45.	2.5	15
27	Clinical heterogeneity in Italian patients with amyotrophic lateral sclerosis. Clinical Genetics, 2012, 82, 83-87.	2.0	13
28	Novel GRN Mutations in Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 62, 1683-1689.	2.6	12
29	Primary Progressive Aphasia. Alzheimer Disease and Associated Disorders, 2019, 33, 42-46.	1.3	12
30	Association of the Variant Cys139Arg at GRN Gene to the Clinical Spectrum of Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2014, 40, 679-685.	2.6	11
31	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. Oncotarget, 2017, 8, 71528-71535.	1.8	11
32	Progranulin Genetic Screening in Frontotemporal Lobar Degeneration Patients From Central Italy. Cellular and Molecular Neurobiology, 2012, 32, 13-16.	3.3	10
33	Genetic Heterogeneity of Alzheimerâ€™s Disease: Embracing Research Partnerships. Journal of Alzheimer's Disease, 2018, 62, 903-911.	2.6	10
34	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
35	Suitability of neuropsychological tests in patients with vascular dementia (VaD). Journal of the Neurological Sciences, 2012, 322, 41-45.	0.6	9
36	Linguistic profiles, brain metabolic patterns and rates of amyloid-Î² biomarker positivity in patients with mixed primary progressive aphasia. Neurobiology of Aging, 2020, 96, 155-164.	3.1	9

#	Article	IF	Citations
37	Different implication of NEDD9 genetic variant in early and late-onset Alzheimer's disease. Neuroscience Letters, 2010, 477, 121-123.	2.1	8
38	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	3.1	8
39	Analyses of the role of the glucocorticoid receptor gene polymorphism (rs41423247) as a potential moderator in the association between childhood overweight, psychopathology, and clinical outcomes in Eating Disorders patients: A 6 years follow up study. Psychiatry Research, 2016, 243, 156-160.	3.3	7
40	Crossed aphasia in nonfluent variant of primary progressive aphasia carrying a GRN mutation. Journal of the Neurological Sciences, 2018, 392, 34-37.	0.6	7
41	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.1	7
42	Association Study of Genetic Variants inCDKN2A/CDKN2BGenes/Loci with Late-Onset Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-4.	2.0	5
43	Advances in imagingâ€“genetic relationships for Alzheimerâ€™s disease: clinical implications. Neurodegenerative Disease Management, 2014, 4, 73-81.	2.2	5
44	Low Florbetapir PET Uptake and Normal AÎ²1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier. Journal of Alzheimer's Disease, 2017, 57, 697-703.	2.6	5
45	DAPK1 is Associated with FTD and not with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 13-17.	2.6	4
46	Novel presenilin 1 mutation (Ile408Thr) in an Italian family with late-onset Alzheimerâ€™s disease. Neuroscience Letters, 2016, 610, 150-153.	2.1	4
47	Effects of Multiple Genetic Loci on Age atÂOnset in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2017, 56, 1271-1278.	2.6	4
48	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
49	Association of the New Variant Tyr424Asp at TBK1 Gene with Amyotrophic Lateral Sclerosis and Cognitive Decline. Journal of Alzheimer's Disease, 2017, 61, 41-46.	2.6	3
50	Biomarkers study in atypical dementia: proof of a diagnostic work-up. Neurological Sciences, 2018, 39, 1203-1210.	1.9	3
51	Challenges in Alzheimerâ€™s Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences. Journal of Alzheimer's Disease, 2020, 77, 203-217.	2.6	3
52	FDG PET and the genetics of dementia. Clinical and Translational Imaging, 2013, 1, 235-246.	2.1	2
53	High Frequency of Crossed Aphasia in Dextral in an Italian Cohort of Patients with Logopenic Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2019, 72, 1089-1096.	2.6	2
54	Clinical and neuroimaging profiles to identify C9orf72 â€FTD patients and serum Neurofilament to monitor the progression and the severity of the disease. Neurology and Clinical Neuroscience, 2019, 7, 326-333.	0.4	1

#	Article	IF	Citations
55	A case of limbic encephalitis evolving into a frontotemporal dementiaâ€like picture. Psychogeriatrics, 2020, 20, 355-357.	1.2	0